Rational approach to discover multipotent anti-Alzheimer drugs

被引：232
|
作者：
Rosini, M
Andrisano, V
Bartolini, M
Bolognesi, ML
Hrelia, P
Minarini, A
Tarozzi, A
Melchiorre, C
机构：
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
[2] Univ Bologna, Dept Pharmacol, I-40126 Bologna, Italy
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 02期
关键词：
D O I：
10.1021/jm049112h
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The coupling of two different pharmacophores, each endowed with different biological properties, afforded the hybrid compound lipocrine (7), whose biological profile was markedly improved relative to those of prototypes tacrine and lipoic acid. Lipocrine is the first compound that inhibits the catalytic activity of AChE and AChE-induced amyloid-beta aggregation and protects against reactive oxygen species. Thus, it emerged as a valuable pharmacological tool to investigate Alzheimer's disease and as a promising lead compound for new anti-Alzheimer drugs.
引用
收藏
页码：360 / 363
页数：4
相关论文
共 50 条
  • [41] Looking for the anti-Alzheimer's molecule - A new approach to treating a devastating disease
    不详
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2013, 28 (01): : 94 - 94
  • [42] BRI2 as an anti-Alzheimer gene
    Shuji Matsuda
    Takao Senda
    Medical Molecular Morphology, 2019, 52 : 1 - 7
  • [43] Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs
    Weinstock, M
    Kirschbaum-Slager, N
    Lazarovici, P
    Bejar, C
    Youdim, MBH
    Shoham, S
    NEUROPROTECTIVE AGENTS, 2001, 939 : 148 - 161
  • [44] New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents
    Roldan-Pena, Jesus M.
    Alejandre-Ramos, Daniel
    Lopez, Oscar
    Maya, Ines
    Lagunes, Irene
    Padron, Jose M.
    Pena-Altamira, Luis Emiliano
    Bartolini, Manuela
    Monti, Barbara
    Bolognesi, Maria L.
    Fernandez-Bolanos, Jose G.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 : 761 - 773
  • [45] Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents
    Jameel, Ehtesham
    Meena, Poonam
    Maqbool, Mudasir
    Kumar, Jitendra
    Ahmed, Waqar
    Mumtazuddin, Syed
    Tiwari, Manisha
    Hoda, Nasimul
    Jayaram, B.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 136 : 36 - 51
  • [46] Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline
    Youdim, MBH
    Weinstock, M
    MECHANISMS OF AGEING AND DEVELOPMENT, 2002, 123 (08) : 1081 - 1086
  • [47] Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer's drug discovery
    Alrouji, Mohammed
    Yasmin, Sabina
    Alshammari, Mohammed S.
    Alhumaydhi, Fahad A.
    Sharaf, Sharaf E.
    Shahwan, Moyad
    Shamsi, Anas
    PLOS ONE, 2024, 19 (12):
  • [48] Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows
    Liu, Kunmeng
    Lin, Hui-Heng
    Pi, Rongbiao
    Mak, Shinghung
    Han, Yifan
    Hu, Yuanjia
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (04) : 341 - 350
  • [49] Dimeric and hybrid anti-Alzheimer drug candidates
    Muñoz-Torrero, D
    Camps, P
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (04) : 399 - 422
  • [50] Charge Density Studies on Anti-Alzheimer Agents
    Luger, P.
    Mebs, S.
    Weber, M.
    Dittrich, B.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C969 - C969
12345